# Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non–Small-cell Lung Cancer

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/soluble-programmed-cell-death-ligand-1-as-a-novel-biomarker-for-nivolumab/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Yusuke Okuma,Hiroshi Wakui,Hirofumi Utsumi,Yukiko Sagawa,Yukio Hosomi,Kazuyoshi Kuwano,Sadamu Homma |
| Citations | 146 |
| DOI | 10.1016/j.cllc.2018.04.014 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2799811063 |
| PMID | 29859759 |
| Type | article |
| Year | 2018 |

## Paper authors

- [Yusuke Okuma](https://scholariq.org/researchers/yusuke-okuma/)

## Paper journal

- [Clinical Lung Cancer](https://scholariq.org/journals/clinical-lung-cancer/)

## Paper primary topic

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Paper topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.